An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity

An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity Publisher Pubmed

Babaknejad N^{1, 2, 3} ; Nayeri H³ ; Hemmati R² ; Bahrami S³ ; Esmaillzadeh A^{4, 5, 6}

Show Affiliations

1. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2. Department of Biology, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran
3. Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
4. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
6. Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Hormone and Metabolic Research Published:2018

Abstract

Fibroblast growth factors (FGFs) are responsible for the regulation of a wide range of biological functions, among which cellular proliferation, survival, migration, and differentiation could be pointed out. FGF19 controls the enterohepatic bile acid/cholesterol system, and FGF21 modulates fatty acid/glucose metabolism. Obesity, type 2 diabetes, coronary artery disease, and cancer, all can alter FGF21 circulating concentrations. In contrast to FGF21, metabolic diseases exhibit reduced serum FGF19 levels. Accordingly, FGF19 and FGF21 play important roles in regulating glucose and lipid metabolism. Hence, we present here a timely review on the relationship between FGF19/21 and metabolic diseases, especially obesity, and their probable role in development and treatment of obesity seems necessary. © Georg Thieme Verlag KG Stuttgart New York.

Related Docs

View other Related Docs

1. The Effects of Fasting Diets on Nonalcoholic Fatty Liver Disease, Nutrition Reviews (2023)

2. Impact of Omega-3 Fatty Acids Supplementation on the Gene Expression of Peroxisome Proliferator Activated Receptors-Γ, Α and Fibroblast Growth Factor-21 Serum Levels in Patients With Various Presentation of Metabolic Conditions: A Grade Assessed Systematic Review and Dose–Response Meta-Analysis of Clinical Trials, Frontiers in Nutrition (2023)

3. Prognostic Value of Circulating Macrophage Inhibitory Cytokine 1-Growth Differentiation Factor 15 (Mic-1/Gdf15) in Obesity: Relation With Vascular Endothelial Growth Factor (Vegf) and Markers of Oxidative Stress, Nutrition and Health (2023)

4. Metabolic Syndrome and Nonalcoholic Fatty Liver Disease: Nutritional Approach for Prevention, Journal of Isfahan Medical School (2013)

5. Obesity and Angiogenesis, Journal of Isfahan Medical School (2012)

6. Effects of Dapt on Serum Vascular Endothelial Growth Factor and Its Soluble Receptor in Obese Balb/C Mice, Journal of Isfahan Medical School (2013)

7. Adherence to Low Carbohydrate Diets and Non-Alcoholic Fatty Liver Disease: A Case Control Study, BMC Nutrition (2022)

8. Impact of Bariatric Surgery on Liver Fibrosis Indices Among Type 2 Diabetes Patients in a National Cohort, Scientific Reports (2025)

Experts (# of related papers)

View all Related Experts

Elham Hosseini (1)

Zamzam Paknahad (1)

Style	Citing Format
MLA	Babaknejad N, et al.. "An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity." Hormone and Metabolic Research, vol. 50, no. 6, 2018, pp. 441-452.
APA	Babaknejad N, Nayeri H, Hemmati R, Bahrami S, Esmaillzadeh A (2018). An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity. Hormone and Metabolic Research, 50(6), 441-452.
Chicago	Babaknejad N, Nayeri H, Hemmati R, Bahrami S, Esmaillzadeh A. "An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity." Hormone and Metabolic Research 50, no. 6 (2018): 441-452.
Harvard	Babaknejad N et al. (2018) 'An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity', Hormone and Metabolic Research, 50(6), pp. 441-452.
Vancouver	Babaknejad N, Nayeri H, Hemmati R, Bahrami S, Esmaillzadeh A. An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity. Hormone and Metabolic Research. 2018;50(6):441-452.
BibTex	@article{ author = {Babaknejad N and Nayeri H and Hemmati R and Bahrami S and Esmaillzadeh A}, title = {An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity}, journal = {Hormone and Metabolic Research}, volume = {50}, number = {6}, pages = {441-452}, year = {2018} }
RIS	TY - JOUR AU - Babaknejad N AU - Nayeri H AU - Hemmati R AU - Bahrami S AU - Esmaillzadeh A TI - An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity JO - Hormone and Metabolic Research VL - 50 IS - 6 SP - 441 EP - 452 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract